Is eXoZymes, Inc. (EXOZ) a Buy, Sell, or Hold?
NASDAQ : EXOZ
eXoZymes, Inc.
$5.14 USD
$0.03 (0.59%)
- Volume
- 1.9K
- Average Volume
- 8.17K
- Market Capitalization
- $47.71M
- P/E Ratio
- -4.47
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $18.40
- Year Low
- $4.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.32
Company Overview
NASDAQ
Michael Heltzen
Biotechnology
Healthcare
EXOZ
32
US
USD
Liquidity Metrics
0.76
1.32
1.32
0.91
0.00
Sales & Valuation
-$
0.00
28.45
-6.73
-0.84
Profitability
-$1.09
-$9.16M
0.00%
0.00%
-220.64%
-240.68%
P/E Metrics
-4.47
0.37
0.37
Analyst Price Target & Rating
1/5
0 Analysts
%
Financial Health Scores
-4.94
1/9
$507.58K
$4.02M
$2.49M
-$10.14M
Key Metrics (TTM)
$47.1M
0.00
-4.78
1.32
-220.64%
-362.40%
-22.40%
-14.96%
-123611 days
Company Executives
| Name | Title |
|---|---|
| Paul Opgenorth | Co-Founder & Vice President of Development |
| Tyler Korman | Co-Founder & Chief Scientific Officer |
| Damien A. Perriman | Chief Commercial Officer |
| Fouad Nawaz | Vice President of Finance |
| James U. Bowie | Founder & Independent Director |
| Lasse H. Gorlitz | Vice President of Communications |
| Michael Burns | Executive Vice President of Energy Transition |
| Michael Heltzen | President & Chief Executive Officer |
| Amy Lunzer | Chief of Staff |
Poll Results
No votes yet today — be the first to share your view!
About eXoZymes, Inc. (NASDAQ:EXOZ) Stock
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California. ...
eXoZymes (NASDAQ:EXOZ) Shares Down 1.1% – What’s Next?
2026-08-04 02:21:57
eXoZymes Inc. (NASDAQ: EXOZ - Get Free Report)'s stock price dropped 1.1% on Monday. The stock traded as low as $4.60 and last traded at $4.60. Approximately 12,408 shares were traded during trading, an increase of 30% from the average session volume of 9,573 shares. The stock had previously closed at $4.65. Analyst Upgrades and
2026-07-23 16:15:00
Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes. The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymes Expands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to predict, optimize and accelerate development of cell-free bioprocesses.
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
2026-06-24 16:10:00
Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new cannabinoid-like molecules. NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes' pipeline after NCT advancing towards partnership and commercialization.
eXoZymes Inc. Announces Closing of $6 Million Public Offering
2026-06-17 16:10:00
LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants. The offering consisted of 330,575 units, including 34,440 units sold in partial exercise of over-allotment option, each unit consisting of two shares of common stock and one warrant to purchase one additional share of common stock.
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
2026-06-08 09:00:00
LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant. The Company has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares of common stock and one warrant to purchase one share of common stock.
Frequently Asked Questions
-
What is the current eXoZymes, Inc. (EXOZ) stock price?
-
eXoZymes, Inc.(NASDAQ:EXOZ) stock price is $5.14 in the last trading session. During the trading session, EXOZ stock reached the peak price of $18.4 while $4.35 was the lowest point it dropped to. The percentage change in EXOZ stock occurred in the recent session was 0.59% while the dollar amount for the price change in EXOZ stock was $0.03.
-
EXOZ's industry and sector of operation?
-
The NASDAQ listed EXOZ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EXOZ?
-
Paul Opgenorth | Co-Founder & Vice President of Development
Tyler Korman | Co-Founder & Chief Scientific Officer
Damien A. Perriman | Chief Commercial Officer
Fouad Nawaz | Vice President of Finance
James U. Bowie | Founder & Independent Director -
How many employees does EXOZ have?
-
Number of EXOZ employees currently stands at 32. EXOZ operates from 750 Royal Oaks Drive, Monrovia, CA 91016, US.
-
Link for EXOZ official website?
-
Official Website of EXOZ is: https://exozymes.com
-
How do I contact EXOZ?
-
EXOZ could be contacted at phone #626 415 1488 and can also be accessed through its website. EXOZ operates from 750 Royal Oaks Drive, Monrovia, CA 91016, US.
-
How many shares of EXOZ are traded daily?
-
The average number of EXOZ shares traded daily for last 3 months was 8.17K.
-
What is the market cap of EXOZ currently?
-
The market value of EXOZ currently stands at $47.71M with its latest stock price at $5.14